Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer

• Published in: BioMed research international Vol. 2014; no. 2014; pp. 1 - 7
• Main Authors: Szajewski, Mariusz, Aleksandrowicz-Wrona, Ewa, Gondek, Tomasz, Lysiak-Szydlowska, Wieslawa, Jankun, Jerzy, Skrzypczak-Jankun, Ewa, Szefel, Jarosław
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Puplishing Corporation 01-01-2014; Hindawi Publishing Corporation; Hindawi Limited
• Subjects: Aged; Arachidonate 12-Lipoxygenase - blood; Biomarkers, Tumor - blood; Breast cancer; Colleges & universities; Humans; Male; Men; Plasminogen Activator Inhibitor 1 - blood; Prostate cancer; Prostatic Hyperplasia - blood; Prostatic Hyperplasia - diagnosis; Prostatic Neoplasms - blood; Prostatic Neoplasms - diagnosis; Reproducibility of Results; Sensitivity and Specificity
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2014/102478

In carcinoma of prostate, a causative role of platelet 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) for tumor progression has been firmly established in tumor and/or adjacent tissue. Our goal was to investigate if 12-LOX and/or PAI-1 in patient’s plasma could be used to predict outcome of the disease. The study comprised 149 patients (age 70±9) divided into two groups: a study group with carcinoma confirmed by positive biopsy of prostate (n=116) and a reference group (n=33) with benign prostatic hyperplasia (BPH). The following parameters were determined by the laboratory test in plasma or platelet-rich plasma: protein level of 12-LOX, PAI-1, thromboglobulin (TGB), prostate specific antigen (PSA), C-reactive protein (CRP), hemoglobin (HGB, and hematocrit (HCT), as well as red (RBC) and white blood cells (WBC), number of platelets (PLT), international normalized ratio of blood clotting (INR), and activated partial thromboplastin time (APTT). The only difference of significance was noticed in the concentration of 12-LOX in platelet rich plasma, which was lower in cancer than in BPH group. Standardization to TGB and platelet count increases the sensitivity of the test that might be used as a biomarker to assess risk for prostate cancer in periodically monitored patients.